CTOs on the Move

The Ritedose Corporation,

www.ritedose.com

 
  MANUFACTURING Philosophy The TRC team understands that the actions required to be a successful pharmaceutical manufacturer are more than just completing repetitive and highly detailed tasks accurately; it is the understanding that we...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.ritedose.com
  • 1, Technology Circle
    Columbia, SC USA 29203
  • Phone: 803.806.3300

Executives

Name Title Contact Details

Similar Companies

United Vein Centers

United Vein Centers is Tampas choice for vein care. We have extensive experience treating both varicose & spider veins - particularly our physician, Dr. Wazni.

Berg Pharma

Berg Pharma focuses research on understanding how alterations in metabolism relate to disease onset. The company has a deep pipeline of early-stage technologies in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with use of the Berg Interrogative Biology™ discovery platform that translates biological output into therapeutic candidates, Berg Pharma is well positioned for rapid commercialization of its intellectual capital.

Helvoet Pharma USA

Helvoet Pharma USA is a Pennsauken, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CapsoVision

Please select your location. United States International

Karyopharm

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.